Serum malondialdehyde (MDA) level as a potential biomarker of cancer progression for patients with bladder cancer
References
- 1. TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87.
- 2. SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7.
- 3. FONTEYNE V., OST P., BELLMUNT J., DROZ JP., MONGIAT-ARTUS P., INMAN B., et al. Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol 2018; 73:40.
- 4. KASSOUF W., TRABOULSI SL., KULKARNI GS., BREAU RH., ZLOTTA A., FAIREY A., et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2015; 9(9–10):E690–704.
- 5. VALKO M., IZAKOVIC M., MAZUR M., RHODES CJ., TELSER J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004; 266:37–565.
- 6. KONG Q., BEEL JA., LILLEHEI KO. A threshold concept for cancer therapy. Med Hypotheses. 2000; 5:529–535.
- 7. PISOSCHI AM., POP A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015; 97:55–74.
- 8. GUERAUD F., ATALAY M., BRESGEN N., CIPAK A., ECKL PM., HUC L., JOUANIN I., SIEMS W., UCHIDA K. Chemistry and biochemistry of lipid peroxidation products. Free Radic Res. 2010; 44:1098–1124.
- 9. ESTERBAUER H., SCHAUR RJ., ZOLLNER H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991; 11:81–128.
- 10. FARMER EE., DAVOINE C. Reactive electrophile species. Curr Opin Plant Biol. 200; 10 (4): 380–6.
- 11. BARRERA G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012; 2012:137289.
- 12. HONGLERTSAKUL C., OPANURAKS J., KITTIKOWIT W., BOONLA C., WUNSUWAN R., TOSUKHOWONG P. Increased urinary excretions of oxidative stress biomarkers and sialic acid associated with severity of bladder tumors. The THAI Journal of surgery. 2007; 28:133–137.
- 13. BADRINATH RK., ROBERT AG. Urine based markers of urological malignancy. J Urol. 2001; 165: 600.
- 14. EL GENDY SM., SALAM AIM., EL-WAHAB NA., HUSSEIN MK., GABRY MS., EL-AASER AA. Urinary telomerase activity, C-erbB2, malondialdehyde and nitric oxide as biological markers of bladder cancer. Turk J Biochem. 2006; 31(4); 164–168.
- 15. YALCIN O., KARATAS F., ERULAS FA., OZDEMIR E. The levels of glutathione peroxidaes, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. Br J Uro Int. 2004; 93(6): 863–866.
- 16. KACZMAREK P., BUCZYNSKI A., NIEMIROWICZ J., GNITECKI W., KOCUR E., KARPINSKI J. Lipids peroxidation in platelets in patients with bladder cancer treated with Mycobacterium suspension. Pol Merkuriusz Lek. 2001; 11: 484–6.
- 17. SAWICKA E., KRATZ EM., SZYMAŃSKA B., GUZIK A., WESOŁOWSKI A., KOWAL P., et al. Preliminary study on selected markers of oxidative stress, inflammation and angiogenesis in patients with bladder cancer. Pathol Oncol Res. 2019. doi: 10.1007/s12253-019-00620-5.
- 18. JELIC MD., MANDIC AD., MARICIC SM., SRDJENOVIC BU. Oxidative stress and its role in cancer. J Can Res Ther [Epub ahead of print] [cited 2019 Nov 9].
- 19. GECIT I., ASLAN M., GUNES M., PIRINCCI N., ESEN R., DEMIR H., CEYLAN K. Serum prolidase activity, oxidative stres and nitric oxide levels in patients with bladder cancer. J Cancer Res Clin Oncol 2012; 138:739–743.
- 20. TAI WY., YANG YC., LIN HJ., HUANG CP., CHENG YL., CHEN MF., YEN HL., LIAU I. Interplay between structure and fluidity of model lipid membranes under oxidative attack. The Journal of Physical Chemistry B. 2010; 114 (47): 15642–15649.
- 21. NIMET V., RUCKEN T. Effect of stress induced lipid peroxidation on cell function. International cell biology. 2004; 28(7):517–521.
- 22. SEVEN A., CIVELEK S., INCI E., KORKUT N., BURÇAK G. Evaluation of oxidative stress parameters in blood of patients with laryngeal carcinoma. Clin Biochem J, 1999; 32(5): 69–73.
- 23. BADJATIA N., SATYAM A., SINGH P., SETH A., SHARMA A. Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol J. 2010; 28 (4): 360–7.
- 24. DILLIOGLUGIL MO., MEKIK H., MUEZZINOGLU B., OZKAN TA., DEMIR CG., DILLIOGLUGIL O., et al. Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer. Int Urol Nephrol. 2012; 44:1691–6.
- 25. KOSOVA F., TEMELTAŞ G., ARI Z., LEKILI M. Possible relations between oxidative damage and apoptosis in benign prostate hyperplasia and prostate cancer patients. Tumour Biol. 2014; 35:4295–9.
- 26. EL-FAR M., ABOL-ENEIN H., ZAKARIA A., EL-GEDAMY M. Evaluation of nitric oxide and malondialdehyde levels in serum of Egyptian patients with bladder and renal tumors: Potential use as medicinal biomarkers. World J Pharm Pharm Sci. 2014; 3:87–101.
Language: English
Page range: 146 - 152
Submitted on: Feb 14, 2020
Published on: Aug 10, 2020
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2020 Zahid Lepara, Orhan Lepara, Almir Fajkić, Damir Rebić, Jasmin Alić, Hajrudin Spahović, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.